02.Establishment of IP-R&D plan(Brand Identity) for HIEstem Designated as a National Project (120 million KRW)
12.Medinno is selected by the Ministry of Employment and Labor as a youth-friendly hidden champion
12.HIEstem for IVH is Designated as one of 'Orphan Drugs in Development Stage' from MFDS, No.2021-633
11.A License for the Management of Human cells etc. was Granted by MFDS
10.HIEstem (IVH) SIT is Approved by MFDS through changing the clinical protocol for HIEstem (HIE)
05.HIEstem for HIE is Designated as one of 'Orphan Drugs in Development Stage' from MFDS, No.2021-192
04.Registration of 2nd R&D Center (Seoul, South Korea)
03.Establishment of IP-R&D plan for HIEstem Designated as a National Project
(100 million KRW)
11.Series B Funding (paid-in capital of 13 billion KRW)
11.Commercialization of Pipelines is Designated as a National Project
(750 million KRW)
06.GMP facility ‘M-Plant’ is Established
(Seoul, South Korea)
05.HIEstem is Designated as a National Project
(1.74 billion KRW)
02.Phase I Clinical trial on HIEstem for HIE Started
01.MOU is signed with IPscent for Commercialization of Pipelines
12.ahNSCs for SCI(Neurospine) is designated as a National Project (187 million KRW)
07.Series A Funding (paid-in capital of 8 billion KRW)
06.HIEstem (HIE) SIT is Approved by MFDS
02.HIEstem (HIE) IIT is Approved by MFDS (a.k.a. KFDA)
07.Seed Funding (paid-in capital of 2 billion KRW)
05.Registration of R&D Center (Suwon, South Korea)
03.MEDINNO Inc. is Established (Seoul, South Korea)
NEWSROOM
CAREERS
CONTACT US